Skip to content

Assessment of Blood Viscosity in ARDS (Acute Respiratory Distress Syndrome)

Assessment of Blood Viscosity in ARDS

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07823296
Acronym
VISC-ARDS
Enrollment
46
Registered
2026-09-16
Start date
2026-10-01
Completion date
2028-01-01
Last updated
2026-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ARDS

Keywords

ards, blood viscosity, prospective case-control study

Brief summary

Acute respiratory distress syndrome (ARDS) is characterized by damage to the alveolar-capillary membrane, resulting in hypoxemia, decreased pulmonary compliance, and hemodynamic changes. Critical conditions (hypoxia; septic shock associated with ARDS) can alter blood viscosity. These changes in viscosity can affect blood flow and hemodynamics. There is only one clinical study that has measured one of the determinants of blood viscosity in ARDS (deformability), even though other parameters are involved in viscosity (elongation, deformability, hematocrit, etc.), and it is possible to measure blood viscosity comprehensively. To date, therefore, no study has evaluated the various parameters of blood viscosity in ARDS. The aim of this study is to investigate hyperviscosity in patients with ARDS and to assess whether this hyperviscosity correlates with respiratory or hemodynamic changes. The investigators will therefore compare blood viscosity and its determinants in patients admitted to the intensive care unit for ARDS and in patients admitted for other reasons (excluding ARDS or sepsis/septic shock). The investigators will also conduct a longitudinal assessment of changes in hemodynamic, respiratory, and viscosity parameters during ARDS

Interventions

BIOLOGICALBlood draws (peripheral venous puncture)

Procedure performed by intensive care nurses. Case group : Daily blood draws (4 mL) for 7 days. Control group : blood draws (4 mL) on Day 1.

OTHERBlood draws (arterial catheter, central venous line, or Swan-Ganz catheter)

Case group : For patients with an arterial catheter, central venous line, or Swan-Ganz catheter, an additional blood sample will be collected on Day 1.

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Case Group Inclusion Criteria: * Age ≥ 18 ans * Moderate-to-severe ARDS according to the global definition: * with PaO₂/FiO₂ ≤ 200 mmHg (based on arterial blood gas analysis in patients receiving invasive or non-invasive mechanical ventilation or high-flow nasal oxygen therapy). * Participation agreement obtained (either from the patient themselves or from a relative)

Exclusion criteria

* ARDS that has been present for more than 72 hours * Terminally ill patient with death expected within 24 hours * Patient who has received a blood transfusion within the past month * Patient with a known hematologic malignancy (lymphoma; myeloma; acute or chronic leukemia) * Patient with a known hemoglobinopathy. * Hemorrhagic shock * Hemoglobin \< 70 g/dL Control group Inclusion Criteria: * Age ≥ 18 ans * Participation agreement obtained (either from the patient themselves or from a relative)

Design outcomes

Primary

MeasureTime frameDescription
Comparison of Blood Viscosity in Patients with ARDS and Control Group on Day 1At day 1Blood viscosity will be determined after complete oxygenation of the blood, at native hematocrit, at a temperature of 25 °C. Measurements will be performed at different shear rates (11.5, 22.5, 45, 90, and 225 s-¹) using a cone-plate viscometer (Brookfield DVII+ equipped with a CPE40 cone, Brookfield Engineering Labs, Natick, MA, USA). This technique is based on applying a well-defined shear rate gradient between a moving conical surface and a fixed flat surface, with the blood sample placed between them. The fluid subjected to this shear resists flow in proportion to its viscosity. The higher the viscosity, the greater the torque required to maintain motion. This approach allows for the precise measurement of the apparent viscosity of blood across a wide range of mechanical stresses, replicating the flow conditions encountered in the bloodstream. The value at 225 s-¹ will be used as the primary endpoint (with an accuracy of 5-10 centipoise at this shear rate).

Countries

France

Contacts

CONTACTHippolyte LEQUAIN, Dr
hippolyte.lequain@chu-lyon.fr0472071281
CONTACTJean-Christophe RICHARD, Pr
j-christophe.richard@chu-lyon.fr0472009272

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 17, 2026